AJANTPHARM vs SAILIFE: Stock Comparison
Ajanta Pharma Limited is the larger company by market capitalisation. Ajanta Pharma Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
AJANTPHARM leads 12; SAILIFE leads 1 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | AJANTPHARM | SAILIFE |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | AJANTPHARM | SAILIFE |
|---|---|---|
| Live Price | ₹3,639.8 | ₹1,457.4 |
| Day Change | -0.51% | -0.96% |
| Volume | 51,825 | 3.24 L |
| 52-Week High | ₹3,796 | ₹1,484.2 |
| 52-Week Low | ₹2,329.9 | ₹783.85 |
| Distance from 52W High | -4.11% | -1.81% |
Valuation
| Metric | AJANTPHARM | SAILIFE |
|---|---|---|
| Market Cap | ₹45,48,258.56 L Cr | ₹30,979 Cr |
| P/E Ratio | 40.21x | 84.93x |
| P/B Ratio | 10.08x | 12.4x |
| EPS | ₹90.63 | ₹16.43 |
| Book Value | ₹362.35 | ₹117.47 |
| Dividend Yield | 1.76% | 0% |
Growth
| Metric | AJANTPHARM | SAILIFE |
|---|---|---|
| Revenue Growth (TTM YoY) | 21.5% | 3.9% |
| EPS Growth (TTM YoY) | 18.6% | 17.6% |
| Qtr Sales Growth | 21.5% | 3.91% |
| Qtr Profit Growth | 18.4% | 17.8% |
Profitability & Leverage
| Metric | AJANTPHARM | SAILIFE |
|---|---|---|
| ROE | 27.1% | 15.4% |
| ROCE | 34.5% | 19.6% |
| Net Margin | 19.38% | 15.81% |
| Operating Margin | 27.5% | 28.8% |
| Debt to Equity | 0.06x | 0.12x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | AJANTPHARM | SAILIFE |
|---|---|---|
| Promoter Holding | 63.48%▼ 2.77 pp | 32.87%▼ 0.08 pp |
| FII Holding | 7.68%▼ 0.58 pp | 19.65%▼ 1.52 pp |
| DII Holding | 21.8%▲ 3.43 pp | 32.71%▲ 1.17 pp |
| Public Holding | 7.03%▼ 0.09 pp | 13.11%▲ 0.43 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Ajanta Pharma Limited and Sai Life Sciences Limited.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.